Dexpramipexole

An investigational drug for neurodegenerative diseases

Dexpramipexole
File:Dexpramipexole.png
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Dexpramipexole is a small molecule drug that has been investigated for its potential use in treating neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). It is a chirally pure form of the drug pramipexole, which is used in the treatment of Parkinson's disease.

Mechanism of Action

Dexpramipexole is believed to work by enhancing the function of mitochondria, the energy-producing organelles in cells. This enhancement may help protect neurons from degeneration, which is a hallmark of diseases like ALS. The exact mechanism by which dexpramipexole exerts its effects is not fully understood, but it is thought to involve the modulation of mitochondrial function and reduction of oxidative stress.

Clinical Development

Dexpramipexole has undergone several clinical trials to assess its efficacy and safety in patients with ALS. Initial studies showed promise, with some patients experiencing a slower progression of the disease. However, a large Phase III clinical trial did not demonstrate a statistically significant benefit in slowing the progression of ALS compared to placebo.

Potential Applications

While the primary focus of dexpramipexole research has been on ALS, there is interest in exploring its potential use in other neurodegenerative conditions, such as Huntington's disease and Alzheimer's disease. The drug's ability to modulate mitochondrial function makes it a candidate for diseases characterized by mitochondrial dysfunction.

Challenges and Future Directions

The failure of dexpramipexole to show significant efficacy in late-stage clinical trials for ALS has led to a reevaluation of its potential. Researchers are investigating whether different dosing regimens, combination therapies, or targeting specific patient subgroups might yield better results. Additionally, ongoing research into the drug's mechanism of action may uncover new therapeutic targets or applications.

Related pages

• Neurodegenerative disease
• Amyotrophic lateral sclerosis
• Mitochondria
• Oxidative stress